Pharmacokinetics in patients with cardiac failure
- PMID: 799548
- DOI: 10.2165/00003088-197601060-00001
Pharmacokinetics in patients with cardiac failure
Abstract
Cardiac failure is often associated with disturbances in cardiac output, autonomic nervous system activity, central and systemic venous pressures, and sodium and water metabolism. These disturbances influence the extent and pattern of tissue perfusion, may lead to tissue hypoxia and visceral congestion, and may alter gastrointestinal motility. By these mechanisms, cardiac failure potentially affects absorption and disposition characteristics of drugs, which may necessitate adjustment in dosage regimen for optimum therapy. Lignocaine is the drug which has been studied most extensively in cardiac failure. Volumes of distribution and clearance are decreased. As a drug whose metabolism is largely limited by liver blood flow, decreased blood flow to the liver accounts for some of the change in clearance, but impaired hepatic metabolism appears also to play a role in some patients. Accumulation of active metabolites of lignocaine and procainamide in patients with cardiac failure can influence therapeutic and toxic effects. Theophylline metabolism, which is largely independent of blood flow, appears to be reduced significantly in patients with severe cardiac failure and necessitates reduction of dosage. In the presence of severe cardiac failure, digoxin clearance may be less than anticipated on the basis of estimates of renal function. Quinidine plasma levels may be higher after single doses due to reduced volume of distribution. Quinidine metabolites are believed not to be pharmacologically active but may create confusion with nonspecific assays. Specific assays are recommended in cardiac failure, especially complicated by renal insufficiency. Data are lacking relating pharmacokinetic alterations to haemodynamic measurements in patients with cardiac failure. Whereas the direction of change in pharmacokinetic parameters may be predicted, variability in the magnitude of change is so great that determination of drug concentration in blood remains as essential adjunct to therapy.
Similar articles
-
Clinical pharmacokinetics of lignocaine.Clin Pharmacokinet. 1978 May-Jun;3(3):177-201. doi: 10.2165/00003088-197803030-00001. Clin Pharmacokinet. 1978. PMID: 350470 Review.
-
Clinical pharmacokinetics in heart failure. An updated review.Clin Pharmacokinet. 1988 Aug;15(2):94-113. doi: 10.2165/00003088-198815020-00002. Clin Pharmacokinet. 1988. PMID: 3064953 Review.
-
Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure.Clin Pharmacokinet. 1976 Nov-Dec;1(6):426-43. doi: 10.2165/00003088-197601060-00003. Clin Pharmacokinet. 1976. PMID: 799549 Review.
-
Effects of congestive heart failure on the pharmacokinetics and pharmacodynamics of antiarrhythmic agents.Am J Cardiol. 1986 Jan 31;57(3):25B-33B. doi: 10.1016/0002-9149(86)90995-1. Am J Cardiol. 1986. PMID: 3080860 Review.
-
The effect of congestive heart failure on quinidine pharmacokinetics.Am Heart J. 1975 Sep;90(3):335-9. doi: 10.1016/0002-8703(75)90322-1. Am Heart J. 1975. PMID: 1163425
Cited by
-
Enalapril and Enalaprilat Pharmacokinetics in Children with Heart Failure Due to Dilated Cardiomyopathy and Congestive Heart Failure after Administration of an Orodispersible Enalapril Minitablet (LENA-Studies).Pharmaceutics. 2022 May 30;14(6):1163. doi: 10.3390/pharmaceutics14061163. Pharmaceutics. 2022. PMID: 35745735 Free PMC article.
-
The Impact of Low Cardiac Output on Propofol Pharmacokinetics across Age Groups-An Investigation Using Physiologically Based Pharmacokinetic Modelling.Pharmaceutics. 2022 Sep 16;14(9):1957. doi: 10.3390/pharmaceutics14091957. Pharmaceutics. 2022. PMID: 36145705 Free PMC article.
-
Drug kinetics in pregnancy.Clin Pharmacokinet. 1977 May-Jun;2(3):167-81. doi: 10.2165/00003088-197702030-00002. Clin Pharmacokinet. 1977. PMID: 328205 Review.
-
Metabolism of procainamide in patients with chronic heart failure, chronic respiratory failure and chronic renal failure.Eur J Clin Pharmacol. 1978 Nov 9;14(1):21-7. doi: 10.1007/BF00560254. Eur J Clin Pharmacol. 1978. PMID: 729603
-
Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 1, drugs administered intravenously).Clin Pharmacokinet. 2013 Mar;52(3):169-85. doi: 10.1007/s40262-012-0029-2. Clin Pharmacokinet. 2013. PMID: 23344981 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials